GRFS - Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Deals and Financings
Grifols (MCE: GRF, [[GRFS]]), a Barcelona maker of plasma-based medicines, acquired a 26% stake in Shanghai RAAS (SHZ: 002252), one of China's largest blood plasma companies, for $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in its US subsidiary, Grifols Diagnostic Solutions, for the Shanghai RAAS stake. As part of the agreement, Shanghai RAAS will become exclusive distributor of Grifols' plasma-based and diagnostic products in China, including Grifol's nucleic acid test ((NAT)) systems used to screen plasma donors for HIV and HCV.
Ambrx, a San Diego biopharma owned